Sidra Medicine highlights advances in pediatric oncology research, precision care
<p>DOHA: Sidra Medicine, a member of Qatar Foundation, has released the findings of its latest Pediatric Oncology Report 2025, to coincide with World Cancer Research Day and Cancer Awareness Month.</p> <p>Developed through Sidra Medicine’s pediatric oncology and translational research programmes, the report highlights the continued progress of pediatric cancer research and precision oncology in…
Doha, Qatar - Sidra Medicine, a Qatar Foundation institution, has unveiled the outcomes of its most recent Pediatric Oncology Report 2025, in conjunction with World Cancer Research Day and Cancer Awareness Month. The report emphasizes the steady advancement of pediatric cancer research and precision oncology in Qatar, demonstrating the integration of genomic and molecular insights with clinical knowledge to deliver more individualized care for children battling cancer.
Dr. Wouter Hendrickx, Director of the Pediatric Oncology Qatar program (SPOQ) at Sidra Medicine, explained that "advances in pediatric oncology research provide clinical teams with a deeper understanding of the specific traits of a child's cancer, aiding in treatment choices. Our efforts align with Qatar's objectives under the Qatar National Vision 2030, striving to enhance healthcare, research, and innovation while bolstering specialized capabilities within the nation.
Through precision medicine strategies, we delve into the molecular features of pediatric tumors to bolster advancements in diagnosis, prognosis, and treatment."
In the period from 2019 to 2025, Sidra Medicine documented 538 pediatric cancer cases, encompassing 355 solid tumors and 183 non-solid cancers. Leukemia constituted 34% of diagnoses, followed by central nervous system malignancies at 22%, lymphoma at 10%, neuroblastoma at 7%, and germ cell tumors at 7%.
SPOQ is a collaborative venture comprising Sidra Medicine's Research branch, Oncology and Hematology, Anatomical Pathology, Hematopathology, and Neurosurgery divisions. Dr. Chiara Cugno, Acting Division Chief of Hematology and Oncology, Clinical Lead for SPOQ and Director of the Advanced Cell Therapy Core at Sidra Medicine, stated, "Advancements in childhood cancer care involve not only the creation of novel treatments, but also the enhancement of diagnosis and the provision of the most appropriate care for each child.
This is what distinguishes Sidra Medicine, as we are among the select few hospitals globally where precision care is integral to the journey of every hematology and oncology patient. We are honored to represent Sidra Medicine as an organization where cancer care and research are at the core of our precision medicine strategy."
Written by urgent.news from The Peninsula Qatar's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
